Why Checkpoint Inhibition Struggles in Solid Tumor Treatment

·

admin

Checkpoint inhibition has revolutionized cancer treatment, offering hope to patients with various malignancies. However, its efficacy in solid tumors remains limited, with response rates often below 15% (1). This article explores the challenges that make checkpoint inhibition an ineffective strategy for many solid tumors and discusses the need for alternative approaches.

1. The Tumor Microenvironment: A Formidable Barrier

The tumor microenvironment (TME) of solid tumors presents significant challenges to checkpoint inhibition:

  • Immunosuppressive cells (Tregs, MDSCs, TAMs) actively suppress anti-tumor immune responses independently of checkpoint ligand expression on themselves or tumor cells via factors such as secretion of immunosuppressive cytokines (2,3,4,5)
  • Hypoxia and acidic pH that creates an unsustainable environment for patients’ immune cells to respond upon checkpoint inhibition (6)
  • Dense extracellular matrix prevents infiltration of both checkpoint inhibitors and immune cells into the tumor core (7)

2. Resistance Mechanisms: Adapting to Evade Treatment

Solid tumors employ various resistance mechanisms to mitigate the efficacy by checkpoint inhibition such as:

  • Acquired resistance through genetic mutations such as JAK1, JAK2 and WNT/β-catenin pathway (8,9).
  • Acquired resistance through loss of neoantigens (10).
  • Continued T cell exhaustion despite checkpoint blockade due to repressive epigenetic state of T cells (11).
  • Downregulation of HLA-A, -B, -C and B2M, significantly reducing their recognition by patients’ cytotoxic T cells (12).

3. Clinical Limitations: Disappointing Outcomes

  • Response rates to checkpoint inhibitors in solid tumors with low mutational burden is extremely low (less than 10%) in clinical trials (13)
  • 5-year Progression-free survival (PFS) for checkpoint inhibitors in immunologically ‘hot’ solid tumors has also been disappointing in clinical trials (less than 20%) due to activated β-catenin pathway (14,15)
  • Secondary resistance develops more than 30% of initial responders, with rates as high as 78% in some trials (16,17)
  • Combination therapies often result in Grade 3 or higher toxicity in more than 50% patients (18,19)

4. The Need for Alternative Strategies

Despite being revolutionary in treating hematological malignancies like Hodgkin’s lymphoma (showing 60-70% response rates in relapsed/refractory cases) and handful to solid tumors such as some types of melanoma (20, 21), checkpoint inhibition has shown limited effectiveness against most other solid tumors, with modest response rates of less than 15%. Solid tumors present multiple challenges, including an immunosuppressive microenvironment, antigen escape mechanisms, and poor immune cell infiltration. To overcome these limitations, emerging cell therapy approaches combine multiple strategies: dual-targeting CAR designs to address tumor heterogeneity, enhanced engineering for improved survival in hostile environments, and strategic combinations with conventional treatments like chemotherapy and radiation. Natural Killer cell therapies offer additional advantages through their innate tumor-killing capabilities and lower toxicity profile. The integration of these approaches with traditional treatments, along with innovations in cell engineering and delivery methods, represents a promising path forward in addressing the complex challenges posed by solid tumors.

5. Conclusion: The Future of Solid Tumor Treatment

While checkpoint inhibition has transformed cancer treatment, its limitations in solid tumors are clear. The future lies in multi-faceted approaches that address these challenges head-on. By embracing innovative strategies, we can pave the way for more effective solid tumor treatments, offering hope to patients diagnosed with solid tumors.

References

  1. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2732329
  2. https://doi.org/10.1038/s41392-021-00670-9
  3. https://doi.org/10.2147/ITT.S55415
  4. https://doi.org/10.1016/j.tranon.2019.12.010
  5. https://doi.org/10.3389/fimmu.2022.915094
  6. https://doi.org/10.1016/j.jddst.2024.105660
  7. https://doi.org/10.3389/fmolb.2019.00160
  8. https://doi.org/10.1056/nejmoa1604958
  9. https://doi.org/10.3389/fonc.2023.1112276
  10. https://doi.org/10.3389/fimmu.2022.915094
  11. https://doi.org/10.1186/s12865-020-00353-0
  12. https://doi.org/10.1038/modpathol.2017.89
  13. https://doi.org/10.1093/oncolo/oyae013
  14. https://doi.org/10.3390/biomedicines11010190
  15. https://doi.org/10.1200/JCO.21.00174
  16. https://doi.org/10.3389/fimmu.2023.1129465
  17. https://doi.org/10.20517/cdr.2019.28
  18. https://www.cancernetwork.com/view/combination-controversies-checkpoint-inhibition-alone-or-combination-treatment-melanoma
  19. https://doi.org/10.3389/fonc.2021.559161
  20. https://doi.org/10.3389/fonc.2023.1288172
  21. https://doi.org/10.1080/21645515.2020.1771986

In:

, ,